A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of a Single 3 Gram Dose of Cefazolin in Adult Subjects Weighing >= 120 kg Scheduled for Surgery

US-G-H-2101

This study is designed to evaluate the pharmacokinetics (PK) of a single 3 gm dose of cefazolin from a DUPLEX container, in adult subjects (weighing \>/= 120 kg) scheduled for surgery. Cefazolin will be administered as a 30-minute intravenous (IV) infusion, per cefazolin Package Insert. Five PK samples per subject will be obtained up to 8 hours after dosing. These data will then be assessed by the validated Cefazolin PK Model to verify there are no significant PK changes within this study population.

2022-04-05

2023-07-13

2023-07-13

Completed

Early phase I

12

Inclusion Criteria: 1. Male or female aged \>/= 18 years; 2. Must weigh \>/= 120 kg 3. Able to understand and sign the Informed Consent Form(s) (ICF); 4. Is scheduled for surgery that is expected to last less than 3 hours; 5. Is scheduled for any type of surgery where a single-dose perioperative cefazolin prophylaxis is appropriate. Exclusion Criteria: 1. If female, is pregnant or lactating/breastfeeding. 2. If female that is of childbearing potential and sexually active, and is not using an effective method of birth control, e.g., oral contraceptives, double barrier methods, hormonal injectable or implanted contraceptives, tubal ligation, or have a partner with a vasectomy. 3. Has a history of renal impairment -- Subject has an eGFR of \<80 mL/min/1.73m2 performed at Screening as calculated by the following equation: 186 x (Creatinine/88.4)-1.154 x (Age)-0.203 x (0.742 if female) x (1.210 if black) (FDA Guidance for Industry Pharmacokinetics in Patients with Impaired Renal Function) 4. Has a known allergy or hypersensitivity to β lactam/cephalosporin antibiotics, corn products, or dextrose-containing products or solutions, or any of the other ingredients of Cefazolin for Injection United States Pharmacopeia (USP) and Dextrose Injection USP in DUPLEX. 5. Has a result of any laboratory test (or repeat test, if done), obtained as standard of care, that is outside the normal limit of the site's laboratory reference range AND is considered by the investigator to be clinically significant. 6. Has had a recent (within 14 days prior to the planned surgery) administration of cefazolin. 7. Has had administration of any medication (e.g., prescription, herbal, over-the-counter medication\[s\] or dietary supplements) known to interact with cefazolin within 5 days prior to the study treatment administration. 8. Has a known history of human immunodeficiency virus, hepatitis B, or hepatitis C infection. 9. Has a current history of medical condition(s), which in the opinion of the investigator, would interfere with the evaluation of the study treatment. 10. Has a known history of organ transplant. 11. Has a clinically relevant disease/dysfunction of or a history of severe cardiac, pulmonary or hepatic disease. 12. Is undergoing any cardiovascular procedure including, but not limited to, major cardiac surgery, cardiac catheterizations (including electrophysiology studies), ablations, automatic implantable cardioverter-defibrillator (AICD), and pacemaker. 13. Has received any other investigational drug/device within 30 days prior to the study treatment administration. 14. Has any planned medical intervention or personal event that might interfere with ability to comply with the study requirements. 15. The subject has any condition that, in the opinion of the investigator, would compromise the safety of the subject or the quality of the data. 16. Is unable or unwilling to adhere to the study-specified procedures and restrictions. 17. Is an employee of the Sponsor, Investigator or study-center, has direct involvement in the study or other studies under the direction of that Investigator or study-center, or is a family member of the employees or the Investigator.

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'interventionModelDescription': 'This is an open-label, non-randomized pharmacokinetic study. All subjects will be receiving the same study treatment, thus blinding is unnecessary.', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'NONE', 'maskingDescription': 'This is an open-label, non-randomized pharmacokinetic study. All subjects will be receiving the same study treatment, thus masking is unnecessary.'}}, 'enrollmentInfo': {'count': 12, 'type': 'ACTUAL'}}

2023-11-18